No products in the cart.
Cat:GMP-h-CA15-3
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Cancer (breast cancer?) and related syndrome. GeneMedi offers paired diagnostics grade Cancer antigen 15-3 (CA15-3) antibodies (monoclonal antibody, mab) and antigens for Cancer (breast cancer?) rapid test kit of Cancer antigen 15-3 (CA15-3) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Cancer (breast cancer? ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Cancer antigen 15-3 (CA15-3) test
Cancer antigen 15-3 (CA15-3) is a protein made by a variety of cells, particularly breast cancer cells. The protein moves into the blood, where it can be measured.
CA15-3 levels are higher than normal in most women with breast cancer that has spread to other parts of the body (called metastatic breast cancer). Not all types of breast cancer will cause CA 15-3 levels to rise, as some types of cancer cells don’t over-produce the antigen.
Why a CA15-3 test is done
CA15-3 is a tumour marker. It is used to check how breast cancer treatment is working and look for cancer that has come back, or recurred, after treatment.
If you are diagnosed with breast cancer that has spread to other parts of the body, or metastasized, you may have this test, along with other tests such as hormone receptor testing and HER2 status testing.
CA15-3 is not measured for early stage breast cancer because the levels of this protein are rarely higher than normal at this stage.
Product Description
Cat No. of Pruducts
GMP-h-CA15-3-Ag01:Recombinant Human CA15-3 Protein
Product Name
Recombinant Human CA15-3 Protein
Target
Cancer antigen 15-3
Alias of Target/Biomarker
#N/A
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
Cancer antigen 15-3 (CA15-3) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CA15-3 level test of Cancer (breast cancer?) and related syndrome evaluation
Tag
His
Products description
Recombinant Human CA15-3 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-CA15-3-Ab01,GMP-h-CA15-3-Ab02:Anti-Human CA15-3 mouse monoclonal antibody (mAb)
Product Name
Anti-Human CA15-3 mouse monoclonal antibody (mAb)
Target
Cancer antigen 15-3 (CA15-3)
Alias of Target/Biomarker
#N/A
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human Cancer antigen 15-3 (CA15-3) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Cancer antigen 15-3 (CA15-3) antibodies in CA15-3 level test of Cancer (breast cancer?) and related syndrome evaluation.
Tag
mFc
Products description
Anti-Human CA15-3 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Cancer antigen 15-3 (CA15-3) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
